Micro-Cap Announces Strong Nine Month Revenue Results

By: AllPennyStocks.com News

November 19, 2009
The debate has reached loud and harsh levels when it comes to health-care in the United States and who should provide it. But folks on both the left and the right appear to agree on one thing: keeping our bodies sound costs too much, and – just perhaps – there is a place for companies in the private sector to keep those costs on a reasonable plane. One company seems to have gotten that efficiency message, and looks to have been amply rewarded for it.

The company in question is California-based instaCare Corporation (OTCBB:ISCR), which came out with eye-popping financial numbers in the middle week of November. This leading distributor of life-saving prescription drugs and at-home testing diagnostics for the chronically ill reported three-quarter revenues were ahead 58% over last year to $14.6 million, as sales and orders for at-home diagnostics and medical surgical products surged.

ISCR, based in the town of Westlake Village, also reported a rare thing in recession-riddled 2009; black ink! Net income for the first nine months of this year leapt to $1.6 million, as compared to a loss of just less than $17,000. What’s more, instaCare had cash, accounts, inventory and equivalents of $3.4 million as of September 30, 2009 vs. $2.8 million for the same period in 2008, a jump of 21%.

The company’s message about its use of technology is also hitting home. During the first nine months of the year, ISCR announced intellectual property and patent strategies to secure its e-health and EMR technologies for Apple iPhone, Palm Pre and Verizon Windows phones.

ISCR boasts products at the development stage that offer “unique solutions in medical care and management by providing physicians with essential information at the point of care”.

Unlike other medical information systems using standard computer terminals, instaCare uses palm-sized computers (PDA's), enabling doctors to carry, access and update their patients' histories, medication data, and best care guidelines at the point of care.

The benefits for patients and doctors are obvious; less time bogged down with paperwork and more time spent healing. But health-care plans also benefit. The system promises a high degree of formulary compliance; claims move more quickly; costs are brought down for all parties and errors are reduced. All in all, health standards are maintained and enhanced.

The news of the stronger bottom line on November 18 attracted investors the company hadn’t seen for awhile, sending the price to a new 52-week high of 15.2 cents a share, towering over the penny a share the stock suffered back in the dog days of March, when it seemed the entire equity market was sick. ISCR’s confidence in developing its products and getting them to market bode well for its future.

Copyright © 2009 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.